Stay informed on the latest ANDEMBRY® (garadacimab) data
Stay informed on the latest ANDEMBRY® (garadacimab) data
From clinical trial data and real-world evidence to congress presentations — hear experts' insights and take a deep dive into the science behind ANDEMBRY®.
ANDEMBRY® (garadacimab) is indicated for routine prevention of recurrent attacks of hereditary angioedema (HAE) in adult and adolescent patients aged 12 years and older.1
Catch up on our latest conferences
Catch up on our latest conferences
Hear insights from a leading HAE expert from our latest symposium (held during the BSI-CIPN Conference 2025), with presentations on the VANGUARD clinical trial and a real-world patient case study.
EXPERT-LED VIDEOS
Learn more about the ANDEMBRY® clinical trial programme
Dr Thomas Buttgereit describes key findings from the ANDEMBRY® clinical trial programme, including the pivotal phase 3 VANGUARD and Open Label Extension (OLE) trials.
EXPERT-LED VIDEOS
Find out how ANDEMBRY® is being used in clinical practice within available markets
Dr Thomas Buttgereit explains the real-world evidence on how ANDEMBRY® is being used in clinical practice in Germany since launching in March 2025.
EXPERT-LED VIDEOS
Catch up on the patient case study
Dr Thomas Buttgereit shares a case study of a patient who switched to ANDEMBRY® in his clinic.
Explore More
Explore More
Access helpful tools and resources to support patients with HAE
Explore new ways to help your patients navigate their treatment with ANDEMBRY® and BERINERT®.
Learn how ANDEMBRY® is changing the path in HAE
Review key clinical data and the mechanism of action for ANDEMBRY®.
Explore HAE attack reduction with ANDEMBRY® (VANGUARD)
Review key efficacy data from the pivotal phase 3 VANGUARD trial for ANDEMBRY®.
Abbreviations: BSI-CIPN, British Society for Immunology Clinical Immunology Professional Network; HAE, hereditary angioedema; KOL, key opinion leader; OLE, open-label extension.
References:
1. ANDEMBRY® (garadacimab). Summary of Product Characteristics.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple store. Adverse events should also be reported to CSL Behring UK Ltd. on 01444 447405.
GBR-AND-0316 | May 2026.